10-Q · May 11, 2026
Apogee Therapeutics reported a net loss of $74.1 million for Q1 2026, an increase from a net loss of $55.3 million in Q1 2025. The company continues to operate without disclosing revenue figures, but increased R&D…
Earnings analysis · 10-Q
APGE earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The filing presents a well-funded but still loss-making clinical-stage biotechnology company, with $1.3 billion of cash, cash equivalents and marketable securities as of June 30, 2026, but a $160.0 million six-month net…
Read full summary
The filing presents a well-funded but still loss-making clinical-stage biotechnology company, with $1.3 billion of cash, cash equivalents and marketable securities as of June 30, 2026, but a $160.0 million six-month net loss and $721.7 million accumulated deficit. Merger-related regulatory progress is positive, although the transaction remains subject to additional conditions and carries a potential $381.3 million termination fee. No revenue, EPS, margin, cash-flow, segment, or formal quantitative guidance data were disclosed in the provided filing text.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$1.3B liquidity position
Cash, cash equivalents, and short- and long-term marketable securities totaled $1.3 billion as of June 30, 2026, providing substantial liquidity for ongoing operations.
-
Several merger approvals completed
The HSR waiting period expired on August 5, 2026, satisfying one condition to completion of the Merger; German clearance was unconditional and the Austrian Phase 1 review period expired on August 4, 2026.
-
Pipeline investment continues
Management reported a net loss of $160.0 million for the six months ended June 30, 2026 and an accumulated deficit of $721.7 million, underscoring the company’s continued investment in its clinical pipeline.
-
Controls remained effective
Disclosure controls and procedures were concluded effective as of June 30, 2026, and the company reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
What to watch
-
Merger closing and termination risk
Completion of the pending Merger remains uncertain: the ACCC Phase 1 statutory review period is scheduled to expire on September 7, 2026, unless terminated earlier, and other customary closing conditions remain outstanding. If specified termination circumstances occur, Apogee could owe a $381,273,716 termination fee.
-
Revenue-share obligations
The May 2026 Revenue Share Agreement provided $100.0 million at signing and made available up to $700.0 million of additional milestone payments, but those milestones depend on registrational Phase 3 trials and FDA approval by December 31, 2030. Consummation of the Merger would also trigger change-of-control payment obligations to BXLS.
-
Foreign and sole-source supply risk
The company relies on foreign contract manufacturers and disclosed a March 2026 Samsung Biologics labor-union strike vote. Apogee also has sole-source supply relationships for APG990, APG333, and APG808 drug substance and drug product, creating potential clinical-supply disruption risk.
Management's outlook
No quantitative revenue or EPS guidance was provided in the filing. The filing discusses the pending Merger and related conditions, but does not provide a formal operating outlook.
Earlier filings 4
10-K · March 2, 2026
Apogee is a clinical-stage I&I-focused biotech advancing multiple engineered antibody programs (zumilokibart/APG777, APG279, APG273, APG808) with four validated targets. The company entered 2026 with a strong liquidity…
10-Q · November 10, 2025
Apogee reported a GAAP net loss of $65,021,000 for Q3 (three months ended September 30, 2025), or GAAP diluted EPS of -$1.11, compared with a loss of $49,018,000, or EPS -$0.86 in the year-ago quarter. Operating…
10-Q · May 12, 2025
Apogee Therapeutics reported a net loss of $55.3 million for Q1 2025, with diluted EPS of -$0.95, widening compared to a net loss of $32.1 million and EPS of -$0.64 a year earlier. The company had no reported revenue,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.